

# UROLOGIC ONCOLOGY

Seminars and Original Investigations

Table of Contents: Volume 37, Number 6, June 2019

## Letters to Editor

- 341** Reply by authors: Reducing unnecessary biopsies while detecting clinically significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore  
Jan F.M. Verbeek and Monique J. Roobol
- 343** Therapeutic rationale of targeting BCG and immune checkpoints in non-muscle-invasive bladder cancer: Is this the Future?  
Andrea K. Lindner, Tobias Klatter, Eva Comperat, Isabel Heidegger and Renate Pichler
- 346** Purified protein derivative skin test—One swallow does not make a summer. Re: Purified protein derivative skin test reactions are associated with clinical outcomes of patients with nonmuscle invasive bladder cancer treated with induction Bacillus Calmette-Guérin therapy  
Wojciech Krajewski, Romuald Zdrojowy and Anna Kołodziej
- 348** Reducing unnecessary biopsies while detecting significant prostate cancer including cribriform growth with the ERSPC Rotterdam risk calculator and 4Kscore  
Mitchell C. Benson and Stephen Zappala

## Survey Section

- 349** Survey section contribution—Basic/translational research  
Hyung Kim

## Prostate - Laboratory

- 352.e1** Antitumor effect of a dual cancer-specific oncolytic adenovirus on prostate cancer PC-3 cells  
Chuan-xin Cui, Yi-quan Li, Yu-jia Sun, Yi-long Zhu, Jin-bo Fang, Bing Bai, Wen-jie Li, Shan-zhi Li, Yi-zhen Ma, Xiao Li, Wei-hua Wang and Ning-yi Jin

## Prostate - Clinical

- 352.e19** Time from definitive therapy to onset of metastatic disease predicts outcomes in men with metastatic hormone sensitive prostate cancer  
Andrew W. Hahn, David D. Stenehjem, Anitha B. Alex, David M. Gill, Heather H. Cheng, Elizabeth R Kessler, Namita Chittoria, Przemyslaw Twardowski, Ulka Vaishampayan and Neeraj Agarwal
- 352.e25** mpMRI preoperative staging in men treated with antiandrogen and androgen deprivation therapy before robotic prostatectomy  
Samuel A. Gold, David J. VanderWeele, Stephanie Harmon, Jonathan B. Bloom, Fatima Karzai, Graham R. Hale, Shawn Marhamati, Kareem N. Rayn, Sherif Mehralivand, Maria J. Merino, James L. Gulley, Marijo Bilusic, Ravi A. Madan, Peter L. Choyke, Baris Turkbey, William Dahut and Peter A. Pinto
- 353.e1** National practice patterns for lymph node irradiation in 197,000 men receiving external beam radiotherapy for localized prostate cancer  
Adam B. Weiner, Oliver S. Ko, Alec Zhu, Daniel E. Spratt, Jim C. Hu and Edward M. Schaeffer

(contents continued on next page)

## Table of Contents (*continued*)

### **Bladder - Laboratory**

---

- 353.e9** **Sex steroid hormone receptors in bladder cancer: Usefulness in differential diagnosis and implications in histogenesis of bladder cancer**  
Yasuo Imai, Shuhei Noda, Chiaki Matsuyama, Ayako Shimizu and Takao Kamai

### **Bladder - Clinical**

---

- 353.e17** **The impact of squamous histology on survival in patients with muscle-invasive bladder cancer**  
Justin T. Matulay, Solomon L. Woldu, Amy Lim, Vikram M. Narayan, Gen Li, Ashish M. Kamat and Christopher B. Anderson
- 354.e1** **Robotic vs. open cystectomy: How length-of-stay differences relate conditionally to age**  
Kassem Faraj, Yu-Hui H. Chang, Matthew R. Neville, Gail Blodgett, David A. Etzioni, Elizabeth B. Habermann, Paul E. Andrews, Erik P. Castle, Mitchell R. Humphreys and Mark D. Tyson
- 354.e9** **Clinical significance of functional and anatomical classifications in paraganglioma of the urinary bladder**  
Hongyan Lu, Musa Male, Kehua Jiang, Zhangqun Ye, Dongkui Song and Ding Xia
- 354.e19** **Outcomes of nonmetastatic micropapillary variant upper tract urothelial carcinoma**  
Jonathan J. Duplisea, Firas G. Petros, Roger Li, Bryan Fellman, Charles C. Guo, Bogdan A. Czerniak, Arlene O. Siefker-Radtke, John C. Araujo, Colin P.N. Dinney and Surena F. Matin

### **Kidney - Laboratory**

---

- 355.e1** **sE-cadherin is upregulated in serum of patients with renal cell carcinoma and promotes tumor cell dissemination in vitro**  
Igor Tsaour, Tanja Hüsch, Eva Jüngel, Frederike Schneider, Meike Schneider, Axel Haferkamp, Christian Thomas Verena Lieb, Sven Wach, Helge Taubert, Felix K.-H. Chun and Roman A. Blaheta
- 355.e11** **Microvascular density, macrophages, and mast cells in human clear cell renal carcinoma with and without bevacizumab treatment**  
Roberto Tamma, Monica Rutigliano, Giuseppe Lucarelli, Tiziana Annese, Simona Ruggieri, Eliano Cascardi, Anna Napoli, Michele Battaglia and Domenico Ribatti

### **Kidney - Clinical**

---

- 355.e21** **Association between immune-related adverse events and prognosis in patients with metastatic renal cell carcinoma treated with nivolumab**  
Hiroki Ishihara, Toshio Takagi, Tsunenori Kondo, Chie Homma, Hidekazu Tachibana, Hironori Fukuda, Kazuhiko Yoshida, Junpei Iizuka, Hirohito Kobayashi, Masayoshi Okumi, Hideki Ishida and Kazunari Tanabe
- 356.e1** **A comparison of outcomes for standard and multiplex partial nephrectomy in a solitary kidney: The National Cancer Institute experience**  
Joseph A. Baiocco, Mark W. Ball, Asha K. Pappajohn Kareem N. Rayn, Gennady Bratslavsky, Shawna L. Boyle, William M. Linehan and Adam R. Metwalli
- 356.e9** **External validation of the updated Leibovich prognostic models for clear cell and papillary renal cell carcinoma in an Asian population**  
Han Jie Lee, Alvin Lee, Hong Hong Huang and Weber Kam On Lau
- 356.e19** **Economic burden of renal cell carcinoma among older adults in the targeted therapy era**  
Hrishikesh P. Kale, D'Arcy P. Mays, Pramit A. Nadpara, Patricia W. Slattum, Asit K. Paul and Norman V. Carroll

## Table of Contents (*continued*)

### **Seminar Section**

---

- 357**    **Urological cancers and lifestyle: Nudging patients toward healthy behaviors**  
J. Kellogg Parsons
- 359**    **Systematic review of modifiable risk factors for kidney cancer**  
Osamah Al-Bayati, Aws Hasan, Deepak Pruthi, Dharam Kaushik and Michael A. Liss
- 372**    **Prognostic value of nutritional indices and body composition parameters including sarcopenia in patients treated with radiotherapy for urothelial carcinoma of the bladder**  
Judith Stangl-Kremser, David D'Andrea, Mihai Vartolomei, Mohammad Abufaraj, Gregor Goldner, Pascal Baltzer, Shahrokh F. Shariat and Dietmar Tamandl
- 380**    **Lifestyle and nutritional modifiable factors in the prevention and treatment of bladder cancer**  
Marilyn L. Kwan, Brandon Garren, Matthew E. Nielsen and Li Tang
- 387**    **An update of research evidence on nutrition and prostate cancer**  
Pao-Hwa Lin, William Aronson and Stephen J. Freedland